Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic
Abstract The overarching objective of this study was to provide the descriptive epidemiology of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic in Qatar by addressing specific research questions through a series of national epidemiologic studies. Sources of data were the centralized and standardized national databases for SARS-CoV-2 infection. By July 10, 2020, 397,577 individuals had been tested for SARS-CoV-2 using polymerase-chain-reaction (PCR), of whom 110,986 were positive, a positivity cumulative rate of 27.9% (95% CI 27.8–28.1%). As of July 5, case severity rate, based on World Health Organization (WHO) severity classification, was 3.4% and case fatality rate was 1.4 per 1,000 persons. Age was by far the strongest predictor of severe, critical, or fatal infection. PCR positivity of nasopharyngeal/oropharyngeal swabs in a national community survey (May 6–7) including 1,307 participants was 14.9% (95% CI 11.5–19.0%); 58.5% of those testing positive were asymptomatic. Across 448 ad-hoc testing campaigns in workplaces and residential areas including 26,715 individuals, pooled mean PCR positivity was 15.6% (95% CI 13.7–17.7%). SARS-CoV-2 antibody prevalence was 24.0% (95% CI 23.3–24.6%) in 32,970 residual clinical blood specimens. Antibody prevalence was only 47.3% (95% CI 46.2–48.5%) in those who had at least one PCR positive result, but 91.3% (95% CI 89.5–92.9%) among those who were PCR positive < 3 weeks before serology testing. Qatar has experienced a large SARS-CoV-2 epidemic that is rapidly declining, apparently due to growing immunity levels in the population..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Scientific Reports - 11(2021), 1, Seite 15 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Laith J. Abu-Raddad [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1038/s41598-021-85428-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ067815596 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ067815596 | ||
| 003 | DE-627 | ||
| 005 | 20230309072425.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230228s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41598-021-85428-7 |2 doi | |
| 035 | |a (DE-627)DOAJ067815596 | ||
| 035 | |a (DE-599)DOAJ330d87f1ea0e449491cee18fd5726bdb | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a Laith J. Abu-Raddad |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract The overarching objective of this study was to provide the descriptive epidemiology of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic in Qatar by addressing specific research questions through a series of national epidemiologic studies. Sources of data were the centralized and standardized national databases for SARS-CoV-2 infection. By July 10, 2020, 397,577 individuals had been tested for SARS-CoV-2 using polymerase-chain-reaction (PCR), of whom 110,986 were positive, a positivity cumulative rate of 27.9% (95% CI 27.8–28.1%). As of July 5, case severity rate, based on World Health Organization (WHO) severity classification, was 3.4% and case fatality rate was 1.4 per 1,000 persons. Age was by far the strongest predictor of severe, critical, or fatal infection. PCR positivity of nasopharyngeal/oropharyngeal swabs in a national community survey (May 6–7) including 1,307 participants was 14.9% (95% CI 11.5–19.0%); 58.5% of those testing positive were asymptomatic. Across 448 ad-hoc testing campaigns in workplaces and residential areas including 26,715 individuals, pooled mean PCR positivity was 15.6% (95% CI 13.7–17.7%). SARS-CoV-2 antibody prevalence was 24.0% (95% CI 23.3–24.6%) in 32,970 residual clinical blood specimens. Antibody prevalence was only 47.3% (95% CI 46.2–48.5%) in those who had at least one PCR positive result, but 91.3% (95% CI 89.5–92.9%) among those who were PCR positive < 3 weeks before serology testing. Qatar has experienced a large SARS-CoV-2 epidemic that is rapidly declining, apparently due to growing immunity levels in the population. | ||
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 653 | 0 | |a Science | |
| 653 | 0 | |a Q | |
| 700 | 0 | |a Hiam Chemaitelly |e verfasserin |4 aut | |
| 700 | 0 | |a Houssein H. Ayoub |e verfasserin |4 aut | |
| 700 | 0 | |a Zaina Al Kanaani |e verfasserin |4 aut | |
| 700 | 0 | |a Abdullatif Al Khal |e verfasserin |4 aut | |
| 700 | 0 | |a Einas Al Kuwari |e verfasserin |4 aut | |
| 700 | 0 | |a Adeel A. Butt |e verfasserin |4 aut | |
| 700 | 0 | |a Peter Coyle |e verfasserin |4 aut | |
| 700 | 0 | |a Andrew Jeremijenko |e verfasserin |4 aut | |
| 700 | 0 | |a Anvar Hassan Kaleeckal |e verfasserin |4 aut | |
| 700 | 0 | |a Ali Nizar Latif |e verfasserin |4 aut | |
| 700 | 0 | |a Robert C. Owen |e verfasserin |4 aut | |
| 700 | 0 | |a Hanan F. Abdul Rahim |e verfasserin |4 aut | |
| 700 | 0 | |a Samya A. Al Abdulla |e verfasserin |4 aut | |
| 700 | 0 | |a Mohamed G. Al Kuwari |e verfasserin |4 aut | |
| 700 | 0 | |a Mujeeb C. Kandy |e verfasserin |4 aut | |
| 700 | 0 | |a Hatoun Saeb |e verfasserin |4 aut | |
| 700 | 0 | |a Shazia Nadeem N. Ahmed |e verfasserin |4 aut | |
| 700 | 0 | |a Hamad Eid Al Romaihi |e verfasserin |4 aut | |
| 700 | 0 | |a Devendra Bansal |e verfasserin |4 aut | |
| 700 | 0 | |a Louise Dalton |e verfasserin |4 aut | |
| 700 | 0 | |a Mohamed H. Al-Thani |e verfasserin |4 aut | |
| 700 | 0 | |a Roberto Bertollini |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Scientific Reports |d Nature Portfolio, 2011 |g 11(2021), 1, Seite 15 |w (DE-627)DOAJ000049077 |x 20452322 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2021 |g number:1 |g pages:15 |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s41598-021-85428-7 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/330d87f1ea0e449491cee18fd5726bdb |z kostenfrei |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s41598-021-85428-7 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2045-2322 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2021 |e 1 |h 15 | ||